|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2001-12-18
|
|
pubmed:abstractText |
RAC 3, one of the p160 family of co-activators is known to enhance the transcriptional activity of a number of steroid receptors. As co-activators are also known to enhance androgen receptor (AR) activity, we investigated the role of RAC 3 in the context of prostate cancer. In prostate cancer cell lines, we found variable levels of the RAC 3 protein with highest expression seen in AR-positive LNCaP cells, moderate expression in AR-negative PC 3 cells and low-level expression in AR-negative DU 145 cells. Immuno-precipitation studies showed that endogenous RAC 3 interacted with the AR in vivo and transfection assays confirmed that RAC 3 enhanced AR transcriptional activity. In clinical prostate tissue, we found strong RAC 3 mRNA expression and immuno-histochemistry demonstrated that in benign tissue, the protein was expressed predominantly in luminal cells, while in primary malignant epithelium it was more homogeneously expressed. In a series of 37 patients, the levels of RAC 3 expression correlated significantly with tumour grade (P = 0.01) and stage of disease (P = 0.03) but not with serum PSA levels. In addition moderate or high RAC 3 expression was associated with poorer disease-specific survival (P = 0.03). We conclude that RAC 3 is an important co-activator of the AR in the prostate and may have an important role in the progression of prostate cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10027410,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10085091,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10318779,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10364196,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10433957,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10475243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10597231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10654935,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10823921,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10861496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10866308,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10866661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-10965917,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-11027411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-11050174,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-11094166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-11489729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-1587864,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-1708363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-1710537,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-2720778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-7525052,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-8108393,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-8426836,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-8604394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-8643607,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-8674067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-8782817,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9000575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9121485,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9238002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9252329,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9288775,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9482849,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9488734,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9506940,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9541193,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9576916,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9636157,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9667866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9865902,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9890939,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747336-9892017
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androgens,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Receptor Coactivator 3,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Androgen,
http://linkedlifedata.com/resource/pubmed/chemical/Trans-Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
14
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1928-36
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:11747336-Adenocarcinoma,
pubmed-meshheading:11747336-Aged,
pubmed-meshheading:11747336-Aged, 80 and over,
pubmed-meshheading:11747336-Androgens,
pubmed-meshheading:11747336-Disease Progression,
pubmed-meshheading:11747336-Epithelial Cells,
pubmed-meshheading:11747336-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:11747336-Humans,
pubmed-meshheading:11747336-In Situ Hybridization,
pubmed-meshheading:11747336-Male,
pubmed-meshheading:11747336-Middle Aged,
pubmed-meshheading:11747336-Neoplasm Proteins,
pubmed-meshheading:11747336-Neoplasm Staging,
pubmed-meshheading:11747336-Neoplasms, Hormone-Dependent,
pubmed-meshheading:11747336-Nuclear Receptor Coactivator 3,
pubmed-meshheading:11747336-Prostate-Specific Antigen,
pubmed-meshheading:11747336-Prostatic Hyperplasia,
pubmed-meshheading:11747336-Prostatic Neoplasms,
pubmed-meshheading:11747336-RNA, Messenger,
pubmed-meshheading:11747336-RNA, Neoplasm,
pubmed-meshheading:11747336-Receptors, Androgen,
pubmed-meshheading:11747336-Trans-Activators,
pubmed-meshheading:11747336-Transcription, Genetic,
pubmed-meshheading:11747336-Transcription Factors,
pubmed-meshheading:11747336-Transfection,
pubmed-meshheading:11747336-Tumor Cells, Cultured,
pubmed-meshheading:11747336-Tumor Markers, Biological
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
|
|
pubmed:affiliation |
Prostate Research Group, School of Surgical Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
